San Diego-dependent Viking Therapeutics marked itself as a serious competitor while in the weight loss drug marketplace in February right after revealing promising details from the mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when presented being a weekly injection As well as in